Mr Vincent Gnanapragasam

University of Cambridge

University departments
Department of Oncology
Department of Surgery
NHS or other affiliations
Departments of Urology

Position: University Lecturer in Uro-oncology and Consultant Urologist
Personal home page:

PubMed journal articles - click here

Mr Vincent Gnanapragasam is pleased to consider applications from prospective PhD students.

Research description

Vincent Gnanapragasam graduated from Newcastle University. Following basic surgical training, he was one of the first trainees to be funded through a Cancer Research UK PhD for Clinicians and one of the first recipients of a CRUK Clinician Scientist Fellowship given to a surgeon. His early laboratory work led to novel discoveries into the role of endogenous signalling regulators (SEF/SPRED) in prostate cancer development and mechanistic insights into treatment resistance from growth factor inhibitors.

He is currently a University Lecturer at the University of Cambridge, and Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. Vincent’s research covers the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. With collagues, he has developed novel, more accurate, prognostic prediction models for both group stratified cohorts Cambridge Prognostic Groups and for individualised prediction Predict prostate and pioneered risk stratified pathways for active surveillance follow up. These models have been shown to outperform current guideline endorsed risk models and have been adopted into local and regional guidelines. Predict prostate is the only decision aid endorsed by the UK NICE National Guidelines on prostate cancer. He is CI of the TAPS01 study, NIHRi4i funded CAMPROBE study (based on his invention of a new simple device for infection free prostate biopsies), national Predict Prostate patient RCT and multi-centre PRIM biomarker-imaging cancer detection study. His work has been cited in prostate cancer guidelines by NICE and the European Association of Urology. To further interdisciplinary research in prostate cancer he established the Translational Prostate Cancer Group (TPCG) in Cambridge with colleagues from urology, oncology, radiology, pathology and basic science. The TPCG have so far collaborated on >50 peer reviewed papers with a combined grant income of >£3M. He has also established links with STEM scientists to develop biosensors for cancer detection across different technology platforms. 

He is a member of the UK ICGC prostate group and on the clinical steering committee of the International Pan Prostate Cancer Collaborative. He is a founder member of the International GAP3 Active Surveillance consortium. To date he has raised over £4M in personal research funding covering basic, translational and clinical trials research, over £5M as co-investigator and published over 130 peer reviewed papers. He is also joint applicant on research collaboratives that have secured over £70M in funding. 

 His current clinical practice is in precision prostate cancer diagnostics and personalised medicine. He has introduced practice changing innovations including risk-based stratification and tailored surveillance which has standardised patient care and significantly reduced over-treatment. More recently, with colleagues from the TPCG, he has established a platform for integrated genomics and clinical profiling to explore the potential for targeted adjuvant therapies to improve primary cure rates in poor prognosis prostate cancer. 

 In the University of Cambridge, he leads the University Academic Urology Group and established the Cambridge Urology Translational Research and Clinical Trials office which has recruited>1600 patients to various NIHR and portfolio urology trials. He is also directorate lead for urology research. He holds patents and has won numerous prizes for research, including the CE Alken prize, Urological Research Society Medial, Hunterian Professorship and is a recipient of a University of Cambridge Vice Chancellors Award for Research Impact. He is also Visiting Professor at Anglia Ruskin University.

Research Programme
Urological Malignancies
Methods and technologies
Clinical practice
Clinical trials
Gene expression profiling
Magnetic Resonance Imaging (MRI)
Public health
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Thurtle DR, Jenkins VL, Pharoah PD, Gnanapragasam VJ. Understanding of prognosis in non-metastatic prostate cancer: A randomised comparative study 2 of clinician estimates measured against the PREDICT prostate prognostic model. Br J Cancer (2019) IF 5.9 (In Press)

Thurtle DR, Greenberg DC, Lee LS, Huang HH, Pharoah PD, Gnanapragasam VJ. Individual prognosis at diagnosis in non-metastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. PLoS Med (2019) IF 11.7 Mar 12;16(3):e1002758. doi: 10.1371/journal.pmed.1002758.

Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J, Domínguez-Escrig J, Bratt O, Statin P, Muir K, Lophatananon A. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int. (2019) IF 4.5 May 7. doi:10.1111/bju.14800.

Thurtle D, Starling L, Leonard K, Stone T, Gnanapragasam VJ. Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method. J Clin Urol. (2018) IF pending May;11(3):192-199.

Wedge DC et al.Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. (2018) May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. IF 29.6 Mar 2. doi: 10.1038/ng.3221. ICGC Prostate Group.

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med (2018) IF 9 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5. PubMed PMID: 29490658

Thurtle D, Barrett T, Thankappan-Nair V, Koo B, Warren A, Kastner C, Saeb-Parsy K, Kimberley-Duffell J, Gnanapragasam VJ. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int. (2018) Feb 13. doi: 10.1111/bju.14166.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ. Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. Int J Cancer (2017) IF 7.3 Jan 10. doi: 10.1002/ijc.30604..

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS Medicine (2016) IF 14.4

Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, Koo B, Gallagher FA, Doble A, Kastner C, Parker RA. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. Sci Rep (2016) IF 5.2 Oct 17;6:35364. doi:10.1038/srep35364.

The evolutionary history of lethal metastatic prostate cancer. Gundem et al. ICGC Prostate Group, Nature (2015) Apr 16;520(7547):353-7.

Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. DA Greenberg, A Lophtananon, K Wright,K Muir and VJ Gnanapragasam Plos One (2015)Mar 5;10(3):e0119494.

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. M Hong et al  Nature Communications (2015)

Active Surveillance of prostate cancer: A questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the UK Y Philippou, VJ Gnanapragasam BMC Urology (2015)

Comparative oncological and toxicity outcomes of salvage radical prostatectomy versus non-surgical therapies for radio-recurrent prostate cancer: A meta-regression analysis. Y Philippou,  RA Parker, D Volanisc, VJ Gnanapragasam European Urology Focus (2015)

Integration of copy number and transcriptomics improves risk stratification in prostate cancer. H Ross-Adams et al E Bio Medicine (2015)

The ADC ratio of tumor to normal prostate as a method for quantifying diffusion weighted imaging of the prostate. T Barrett, AN Priest, EM Lawrence, DA Goldman, AY Warren, VJ Gnanapragasam, E Sala,, A Gallagher Am J Roentgenol (2015)

Primary radical therapy selection in high-risk non-metastatic prostate cancer. VJ Gnanapragasam, I Syndikus, H Kynaston and T Johnstone Clinical Oncology (2015)

Incidence of needle tract seeding after prostate biopsy for suspected cancer. D Volanis, DE Neal, VJ Gnanapragasam BJU International (2015)

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Cooper CS et al. ICGC Prostate Group, Nat Genet. (2015) Mar 2. doi: 10.1038/ng.3221. [Epub ahead of print]

Multi-transcript profiling in diagnostic archival needle biopsies to investigate predictive biomarker in non-surgical therapy for prostate cancer.N Kachroo, AY Warren and VJ Gnanapragasam BMC Cancer (2014) Sep 16;14:673.

Molecular markers to guide primary radical treatment selection in localised prostate cancer. VJ Gnanapragasam. Expert Reviews in Molecular Diagnostics (2014) Sep;14(7):871-81

Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. Kuru TH, Saeb-Parsy K, Cantiani A, Frey J, Lombardo R, Serrao E, Gaziev G, Koo B, Roethke M, Gnanapragasam V, Warren A, Doble A, Hadaschik B, Kastner C. World J Urol (2014) Aug;32(4):945-50

Prostate cancer performance characteristics of combined T(2)W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion.Lawrence EM, Tang SY,  Barrett T, Koo B, Goldman DA, Warren AY, Axell RG, Doble A, Gallagher FA, Gnanapragasam VJ, Kastner C, Sala E. Eur Radiol. (2014) Jul;24(7):1497-505

Pre-operative 3-tesla diffusion weighted MRI for the qualitative and quantitative assessment of  extracapsular extension in patients with intermediate or high-risk prostate cancer. EM. Lawrence, FA Gallagher, T Barrett, A Warren, AN Priest, E Sala, VJ Gnanapragasam. Am J Roentology (2014) Sep;203(3):W280-6

Changing presentation of prostate cancer in a UK population: 10 year trends in risk profiles in the East of England. DA Greenberg, K Wright, A Lophatanon, K Muir, VJ Gnanapragasam. British Journal of Cancer (2013) Oct 15;109(8):2115-20

Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.­­ AW Nelson, RC Harvey, RA Parker, C Kastner, A Doble, VJ Gnanapragasam PLOS One(2013) 8(2):e57480. doi: 10.1371/journal.pone.0057480

The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer-a systematic review. N Kachroo, VJ Gnanapragasam Journal of Cancer Research and Clinical Oncology (2013) Jan;139(1):1-24.

Evidence for down-regulation of the negative regulator SPRED2 in clinical prostate cancer. N Kachroo, T Valencia, A Warren, VJ Gnanapragasam. British Journal of Cancer (2013) Feb 19;108(3):597-601.

Risk profiles of prostate cancers identified from UK primary care using national guidelines. H Serag, S Banerjee, K S Parsy, S Irving, K White, S Stearn, A Doble, VJ Gnanapragasam. British Journal of Cancer (2012) Jan 31;106(3):436-9      

Front page of the Predict:Prostate website endorsed by NICE. The tool has been accessed and used >24,000 times from >100 countries since its launch.